IRIS UniCatt

Locatelli, Franco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 33.811
NA - Nord America 17.014
EU - Europa 8.480
SA - Sud America 6.639
AF - Africa 740
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 10
AN - Antartide 1
Totale 66.728
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 16.344
US - Stati Uniti d'America 16.197
CN - Cina 7.945
BR - Brasile 5.517
IT - Italia 2.016
VN - Vietnam 2.008
FR - Francia 1.357
ID - Indonesia 1.322
IE - Irlanda 1.211
KR - Corea 1.013
IN - India 948
DE - Germania 922
JP - Giappone 881
BD - Bangladesh 861
RU - Federazione Russa 785
HK - Hong Kong 749
GB - Regno Unito 524
AR - Argentina 454
IQ - Iraq 371
SE - Svezia 364
MX - Messico 306
CA - Canada 286
FI - Finlandia 250
ZA - Sudafrica 214
TR - Turchia 174
NL - Olanda 170
PK - Pakistan 158
AT - Austria 155
VE - Venezuela 152
EC - Ecuador 146
UA - Ucraina 141
PL - Polonia 129
SA - Arabia Saudita 129
MA - Marocco 114
UZ - Uzbekistan 100
CO - Colombia 99
ES - Italia 98
CZ - Repubblica Ceca 93
JO - Giordania 88
PH - Filippine 87
KE - Kenya 77
PY - Paraguay 72
CL - Cile 70
NP - Nepal 68
EG - Egitto 65
MY - Malesia 59
TH - Thailandia 59
AZ - Azerbaigian 54
AE - Emirati Arabi Uniti 51
DZ - Algeria 51
JM - Giamaica 48
PE - Perù 47
UY - Uruguay 47
TN - Tunisia 44
CH - Svizzera 43
ET - Etiopia 42
KZ - Kazakistan 42
IL - Israele 40
OM - Oman 40
CR - Costa Rica 36
LB - Libano 34
IR - Iran 30
BO - Bolivia 29
AU - Australia 26
DO - Repubblica Dominicana 26
SN - Senegal 25
PT - Portogallo 24
BH - Bahrain 23
BG - Bulgaria 22
HN - Honduras 22
NG - Nigeria 22
PA - Panama 21
SY - Repubblica araba siriana 21
AL - Albania 17
BY - Bielorussia 17
LT - Lituania 17
MD - Moldavia 17
PS - Palestinian Territory 17
CI - Costa d'Avorio 16
TT - Trinidad e Tobago 16
BB - Barbados 15
BE - Belgio 15
GE - Georgia 15
RO - Romania 15
NI - Nicaragua 14
KG - Kirghizistan 13
RS - Serbia 13
LV - Lettonia 10
SK - Slovacchia (Repubblica Slovacca) 10
CG - Congo 9
KW - Kuwait 9
AM - Armenia 8
AO - Angola 8
DK - Danimarca 8
GA - Gabon 8
HU - Ungheria 8
MM - Myanmar 8
GR - Grecia 7
QA - Qatar 7
XK - ???statistics.table.value.countryCode.XK??? 7
Totale 66.582
Salva come PNG Salva come JPEG
Città #
Singapore 7.941
San Jose 3.903
Ashburn 3.115
Hefei 2.977
Jakarta 1.282
Dublin 1.207
Lauterbourg 1.046
Seoul 995
Kent 878
Tokyo 858
Ho Chi Minh City 699
Hong Kong 692
Los Angeles 662
Beijing 571
Moscow 534
Milan 489
Hyderabad 488
Hanoi 469
São Paulo 463
New York 395
Dallas 372
Boardman 339
Frankfurt am Main 328
Council Bluffs 295
Rome 287
Santa Clara 287
Washington 270
Nuremberg 267
Chicago 244
Rio de Janeiro 165
Buffalo 164
St Louis 155
Helsinki 132
Brooklyn 129
Paris 124
Baghdad 119
Shanghai 114
Belo Horizonte 113
Chandler 112
London 109
Johannesburg 106
Brasília 104
Munich 104
Seattle 102
Dhaka 94
Curitiba 93
San Francisco 93
Atlanta 91
Mexico City 90
Warsaw 90
Da Nang 88
Amman 82
Haiphong 82
Porto Alegre 82
Brno 81
Tashkent 80
Campinas 75
Memphis 75
Nairobi 73
Lappeenranta 71
Montreal 71
Orem 71
Boston 70
Toronto 68
Arezzo 64
Pune 64
Amsterdam 59
Guayaquil 59
Vienna 58
Bologna 57
Houston 57
Phoenix 56
Bangkok 55
Chennai 53
Erbil 53
Jacksonville 52
The Dalles 51
Quito 49
Baku 48
Buenos Aires 48
Cape Town 46
Guarulhos 46
Ribeirão Preto 46
Charlotte 45
Guangzhou 44
Istanbul 44
Salvador 44
Goiânia 43
Montevideo 43
Caracas 42
Riyadh 42
Denver 41
Lahore 41
Mumbai 41
Philadelphia 39
Busto Arsizio 38
Las Vegas 38
Recife 38
Addis Ababa 37
Cairo 37
Totale 37.543
Salva come PNG Salva come JPEG
Nome #
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease 256
Cilostazol promotes angiogenesis after peripheral ischemia through a VEGF-dependent mechanism 252
Advancements and challenges in CAR T cell therapy in autoimmune diseases 188
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma 159
Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells 154
Biological, functional and genetic characterization of bone marrow-derived mesenchymal stromal cells from pediatric patients affected by acute lymphoblastic leukemia 152
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. Reply 151
Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party 145
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 139
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 138
Mesenchymal stem/stromal cells: a new ''cells as drugs'' paradigm. Efficacy and critical aspects in cell therapy 130
Proteomics study of peripheral blood mononuclear cells in down syndrome children 128
Achievement of operational tolerance in a pediatric liver transplant recipient following successful hematopoietic stem cell transplantation from a different donor 123
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia 119
Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma 119
KRAS and CREBBP mutations: A relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia 117
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia 116
How I treat relapsed childhood acute lymphoblastic leukemia 115
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial 114
Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party 112
Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study 111
Dasatinib in the Management of Pediatric Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 111
Analysis of X-chromosome inactivation and presumptive expression of the Wiskott-Aldrich syndrome (WAS) gene in hematopoietic cell lineages of a thrombocytopenic carrier female of WAS 111
Dynamic inosinome profiles reveal novel patient stratification and gender-specific differences in glioblastoma 110
CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia 109
Does the emergence and persistence of donor-derived leukaemia-reactive cytotoxic T lymphocytes protect patients given an allogeneic BMT from recurrence? Results of a preliminary study 106
Inhibition of natural killer cell cytotoxicity by interleukin-6: Implications for the pathogenesis of macrophage activation syndrome 104
AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity 104
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 102
Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP) 101
Usefulness of 18F-FDG PET/CT in an Unusual Case of Solid-Pseudopapillary Pancreatic Tumor in Childhood With Aggressive Behavior 100
Busulfan–fludarabine- or treosulfan–fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties 99
Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: An I-BFM Study Group collaboration 98
Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response 98
Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel 98
Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study 97
Identification of a new HLA-B*44 allele, HLA-B*44:02:68, by next generation sequencing 97
Exagamglogene Autotemcel for Severe Sickle Cell Disease 97
MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs 96
First experience of combined enzyme replacement therapy and hematopoietic stem cell transplantation in alpha-mannosidosis 95
Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant 93
T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results 92
Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing 91
Fecal microbiota transplantation for the treatment of steroid-refractory, intestinal, graft-versus-host disease in a pediatric patient 91
Autophagy and cancer stem cells: molecular mechanisms and therapeutic applications 90
T-Cell Defects Associated to Lack of Spike-Specific Antibodies after BNT162b2 Full Immunization Followed by a Booster Dose in Patients with Common Variable Immune Deficiencies 90
Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches 90
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL 90
Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study 90
Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience 89
EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD 89
Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS 88
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 87
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 87
The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx) 87
Engineered mucoperiosteal scaffold for cleft palate regeneration towards the non-immunogenic transplantation 87
Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease 87
Outcome of children with acute leukemia given HLA-haploidentical HSCT after ab T-cell and B-cell depletion 86
Human leukocyte antigen evolutionary divergence influences outcomes of paediatric patients and young adults affected by malignant disorders given allogeneic haematopoietic stem cell transplantation from unrelated donors 86
Decellularized esophageal tubular scaffold microperforated by quantum molecular resonance technology and seeded with mesenchymal stromal cells for tissue engineering esophageal regeneration 86
Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group 85
The role of allogeneic hematopoietic stem cell transplantation in pediatric leukemia 84
Outcome of very late relapse in children with acute lymphoblastic leukemia 84
Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus 84
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders 84
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients 83
A case of SARS-CoV-2 Omicron reinfection resulting in a significant immunity boost in a paediatric patient affected by B-cell acute lymphoblastic leukemia 83
Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients 83
Donor natural killer cells trigger production of β-2-microglobulin to enhance post–bone marrow transplant immunity 82
T lymphocytes against solid malignancies: Winning ways to defeat tumours 82
Autologous bone marrow transplantation for treatment of isolated central nervous system relapse of childhood acute lymphoblastic leukemia. AIEOP/FONOP-TMO group. Associzione Italiana Emato-Oncologia Pediatrica 82
Haematopoetic stem cell transplantation for refractory autoimmune cytopenia 82
Case Report: Trichosporon japonicum Fungemia in a Pediatric Patient With Refractory Acute B Cell Lymphoblastic Leukemia 82
Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival 82
Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations 82
TFG binds LC3C to regulate ULK1 localization and autophagosome formation 82
Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma 81
Natural killer cells in the treatment of high-risk acute leukaemia 80
Correlation of rhinovirus load in the respiratory tract and clinical symptoms in hospitalized immunocompetent and immunocompromised patients 80
Impact of HLA mismatch direction on outcomes after umbilical cord blood transplantation for hematological malignant disorders: a retrospective Eurocord-EBMT analysis 80
Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia 80
Usefulness of 18F-FDG PET/CT in an unusual case of solid-pseudopapillary pancreatic tumor in childhood with aggressive behavior. 80
Characterization of KIR+ NK cell subsets with a monoclonal antibody selectively recognizing KIR2DL1 and blocking the specific interaction with HLA-C 79
Busulfan 79
Frequency of donor cytotoxic T cell precursors does not correlate with occurrence of acute graft-versus-host disease in children transplanted using unrelated donors 79
Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference 79
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines 79
Systematic identification of edited microRNAs in the human brain 79
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 79
Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen 78
Low-Grade Gliomas in Patients with Noonan Syndrome: Case-Based Review of the Literature 78
A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome 78
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors 78
Betibeglogene autotemcel gene therapy for non–β0/β0 genotype β-thalassemia 78
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia 78
Direct involvement of cranial nerve V at diagnosis in patients with diffuse intrinsic pontine glioma: A potential magnetic resonance predictor of short-term survival 77
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study 77
Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent 77
ADAR2 editing activity in newly diagnosed versus relapsed pediatric high-grade astrocytomas 77
Granular acute lymphoblastic leukemia in children. "Aieop Cooperative Group for Cytology of Acute Leukemias" 76
Totale 9.959
Salva come PNG Salva come JPEG
Categoria #
all - tutte 390.054
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 390.054
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022142 9 9 5 5 8 6 5 18 7 10 24 36
2022/20231.335 34 47 20 46 27 50 10 38 696 249 68 50
2023/20247.212 213 1.307 421 200 577 1.217 322 292 199 580 692 1.192
2024/202517.567 272 285 1.297 292 668 555 350 433 3.288 1.354 5.052 3.721
2025/202641.589 7.091 1.753 3.717 3.777 6.266 1.810 7.068 1.841 2.335 2.473 1.741 1.717
Totale 68.250